- Home
- KROS vs ATRO Comparison
KROS vs ATRO Comparison
Compare KROS & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | ATRO |
|---|---|---|
| Founded | 2015 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 1.9B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | KROS | ATRO |
|---|---|---|
| Price | $20.25 | $54.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | $22.20 | ★ $61.50 |
| AVG Volume (30 Days) | ★ 742.6K | 606.6K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | $246,718,000.00 | ★ $830,601,000.00 |
| Revenue This Year | $6,924.79 | $9.39 |
| Revenue Next Year | N/A | $11.52 |
| P/E Ratio | $12.87 | ★ N/A |
| Revenue Growth | ★ 37798.31 | 6.19 |
| 52 Week Low | $9.12 | $15.43 |
| 52 Week High | $22.55 | $56.72 |
Technical Indicators
Market Signals| Indicator | KROS | ATRO |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 56.46 |
| Support Level | $19.76 | $54.44 |
| Resistance Level | $21.76 | $56.22 |
| Average True Range (ATR) | 0.71 | 2.25 |
| MACD | -0.22 | 0.05 |
| Stochastic Oscillator | 20.49 | 70.67 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.